325.28
price up icon1.49%   4.76
pre-market  Pre-mercato:  325.53   0.25   +0.08%
loading
Precedente Chiudi:
$320.52
Aprire:
$321.57
Volume 24 ore:
1.27M
Relative Volume:
1.37
Capitalizzazione di mercato:
$42.41B
Reddito:
$2.35B
Utile/perdita netta:
$-269.70M
Rapporto P/E:
-155.64
EPS:
-2.09
Flusso di cassa netto:
$-75.39M
1 W Prestazione:
+4.55%
1M Prestazione:
+5.03%
6M Prestazione:
+22.04%
1 anno Prestazione:
+38.07%
Intervallo 1D:
Value
$320.18
$326.30
Intervallo di 1 settimana:
Value
$311.25
$329.87
Portata 52W:
Value
$205.87
$333.70

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Nome
Alnylam Pharmaceuticals Inc
Name
Telefono
(617) 551-8200
Name
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Dipendente
2,230
Name
Cinguettio
@alnylam
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ALNY's Discussions on Twitter

Confronta ALNY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-21 Iniziato Truist Buy
2025-03-31 Iniziato Redburn Atlantic Buy
2025-03-24 Aggiornamento JP Morgan Neutral → Overweight
2024-11-12 Downgrade Wolfe Research Peer Perform → Underperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-08-16 Aggiornamento Goldman Neutral → Buy
2024-02-16 Downgrade Goldman Buy → Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-08 Iniziato Wells Fargo Equal Weight
2023-10-11 Downgrade Oppenheimer Outperform → Perform
2023-09-29 Iniziato Raymond James Outperform
2023-05-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-26 Iniziato SMBC Nikko Neutral
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Buy
2022-09-09 Ripresa Morgan Stanley Equal-Weight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-27 Downgrade Guggenheim Buy → Neutral
2022-06-07 Iniziato William Blair Outperform
2022-04-25 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-03-01 Iniziato Citigroup Buy
2022-02-03 Aggiornamento Guggenheim Neutral → Buy
2022-01-03 Aggiornamento Piper Sandler Neutral → Overweight
2021-11-22 Aggiornamento Goldman Neutral → Buy
2021-11-22 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Aggiornamento Oppenheimer Perform → Outperform
2021-10-04 Aggiornamento UBS Neutral → Buy
2021-08-04 Downgrade Piper Sandler Overweight → Neutral
2021-02-22 Downgrade Guggenheim Buy → Neutral
2021-02-12 Downgrade Citigroup Buy → Neutral
2021-02-12 Reiterato H.C. Wainwright Buy
2021-01-25 Downgrade BMO Capital Markets Outperform → Market Perform
2020-09-30 Ripresa Berenberg Hold
2020-09-08 Iniziato Citigroup Buy
2020-08-11 Downgrade Oppenheimer Outperform → Perform
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2020-05-07 Downgrade JP Morgan Overweight → Neutral
2020-04-24 Ripresa Evercore ISI Outperform
2020-03-19 Iniziato Berenberg Buy
2019-12-19 Reiterato Chardan Capital Markets Buy
2019-11-20 Iniziato Oppenheimer Outperform
2019-11-13 Iniziato BofA/Merrill Buy
2019-05-23 Ripresa Goldman Neutral
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-06 Aggiornamento Evercore ISI In-line → Outperform
2019-03-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-01-23 Iniziato UBS Neutral
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-13 Reiterato Stifel Buy
2018-08-07 Aggiornamento Stifel Hold → Buy
2018-05-04 Reiterato Stifel Hold
2018-03-28 Iniziato Evercore ISI In-line
Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

pulisher
Jul 22, 2025

What drives Alnylam Pharmaceuticals Inc. stock priceFree Stock Selection - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Alnylam Pharmaceuticals Inc. stockOutperformance with explosive growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛

Jul 22, 2025
pulisher
Jul 22, 2025

Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey

Jul 21, 2025
pulisher
Jul 21, 2025

Lexicography: Clear And Unequivocal - The National Law Review

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jul 21, 2025
pulisher
Jul 19, 2025

Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail

Jul 19, 2025
pulisher
Jul 18, 2025

Alnylam’s ALN-4324: A Promising Step in Obesity Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

Alnylam’s HELIOS-A Study: A Promising Update for hATTR Amyloidosis Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam Pharmaceuticals stock price target raised to $290 by Cantor Fitzgerald - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Health Check: How Prudently Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Use Debt? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam's 2025 Earnings and Strategic Momentum: A Case for Biotech Leadership and Long-Term Value Creation - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results - Business Wire

Jul 17, 2025
pulisher
Jul 16, 2025

Alnylam’s ConTTRibute Study: A Closer Look at ATTR Amyloidosis Treatment - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

Amvuttra gains UK approval for heart form of ATTR amyloidosis - The Pharma Letter

Jul 16, 2025
pulisher
Jul 16, 2025

JPMorgan raises Alnylam Pharmaceuticals stock price target on Amvuttra forecast - Investing.com Canada

Jul 16, 2025
pulisher
Jul 15, 2025

Hemophilia Clinical Trials, Companies, Therapeutic - openPR.com

Jul 15, 2025
pulisher
Jul 15, 2025

Alnylam Pharmaceuticals Trading Volume Surges to $289 Million Ranking 356th in Daily Volume - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alnylam Pharma (ALNY) Receives a Buy from Citi - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

Alnylam Pharmaceuticals Trading Volume Drops 41.67% to $199 Million Ranking 472nd - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Jefferies reiterates Buy rating on Alnylam Pharmaceuticals stock, citing strong Amvuttra sales - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

What makes Alnylam Pharmaceuticals Inc. stock price move sharplyFree Top Growth Stock Recommendations - beatles.ru

Jul 14, 2025
pulisher
Jul 11, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 11, 2025

Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com

Jul 11, 2025
pulisher
Jul 11, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised by Citigroup | ALNY Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Alnylam (ALNY) Receives Price Target Boost from Citi | ALNY Stoc - GuruFocus

Jul 11, 2025
pulisher
Jul 07, 2025

Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 06, 2025

Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com

Jul 06, 2025
pulisher
Jul 04, 2025

BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN

Jul 04, 2025
pulisher
Jul 02, 2025

Alnylam Beats Acuitas Claim on Patents in Pfizer Shot Suit (1) - Bloomberg Law News

Jul 02, 2025
pulisher
Jul 01, 2025

Alnylam's Norton site is 'springboard' for expanding manufacturing capacity - The Business Journals

Jul 01, 2025
pulisher
Jul 01, 2025

Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab - Law360

Jul 01, 2025
pulisher
Jun 30, 2025

Alnylam Pharmaceuticals stock hits all-time high at 326.12 USD - Investing.com

Jun 30, 2025
pulisher
Jun 29, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $377.00 at Needham & Company LLC - MarketBeat

Jun 29, 2025
pulisher
Jun 26, 2025

Needham Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $377 | ALNY Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Become Profitable? - Yahoo Finance

Jun 26, 2025
pulisher
Jun 20, 2025

Alnylam Stock Plummets 31.67% with 2.10 Billion Shares Traded Ranking 423rd in Volume Amid Legal Victory - AInvest

Jun 20, 2025
pulisher
Jun 19, 2025

Alnylam names Pushkal Garg as EVP, chief research and development officer - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Alnylam Pharma Appoints New Chief R&D Officer - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener

Jun 18, 2025

Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$571.23
price up icon 0.90%
biotechnology ONC
$295.59
price up icon 1.25%
$111.44
price up icon 2.32%
$560.93
price up icon 2.82%
$26.54
price up icon 0.76%
Capitalizzazione:     |  Volume (24 ore):